Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
Yun Li,Junfeng Lin,Zihui Wang,Zhufeng Wang,Lunfang Tan,Shuyi Liu,Jinhai Huang,Yi Gao,Jinping Zheng
DOI: https://doi.org/10.2147/COPD.S385733
2022-10-18
International Journal of COPD
Abstract:Yun Li &ast, Junfeng Lin &ast, Zihui Wang &ast, Zhufeng Wang, Lunfang Tan, Shuyi Liu, Jinhai Huang, Yi Gao, Jinping Zheng National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yi Gao; Jinping Zheng, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Yuexiu District, Guangzhou, 510120, People's Republic of China, Tel +86 20 83062869, Fax +86 20 83062729, Email ; Background: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of > 10% relative to the predicted value in forced expiratory volume in 1 second (FEV 1 ) or forced vital capacity (FVC). We aimed to explore the differences between the 2005 and 2021 ERS/ATS criteria applied to patients with asthma as well as chronic obstructive pulmonary disease (COPD). Methods: BDR test data about asthma patients aged 6– 80 years and COPD patients aged 18– 80 years were derived from the National Respiratory Medicine Center, First Affiliated Hospital of Guangzhou Medical University, from January 2017 to March 2022. BDR results defined by the 2005 and 2021 ERS/ATS criteria were named 2005-BDR and 2021-BDR, respectively. We compared differences between 2005-BDR and 2021-BDR and analyzed the trend in the proportion of positive BDR (BDR+) with the level of airflow obstruction. Results: A total of 4457 patients with asthma and 7764 patients with COPD were included in the analysis. The percentages of 2005-BDR+ and 2021-BDR+ were 63.32% and 52.84% for asthma, 30.92% and 22.94% for COPD, respectively. Of patients with 2005-BDR+, 81.86% for asthma and 70.18% for COPD showed 2021-BDR+ results, and these patients had higher FEV 1 %pred, FVC%pred (all P 12% of baseline but <200mL. 11 Previous studies showed that BDR expressed as the percent chang -Abstract Truncated-
respiratory system